What's happening
This bill requires prescription drug manufacturers to notify the state and publicly disclose significant price increases in New York.
Why it matters
Enhances transparency on drug pricing. By requiring advance notice and public disclosure of significant price hikes, the bill aims to give patients, insurers, and policymakers more insight into drug pricing practices, potentially empowering more informed health care decisions and policy responses.
Targets substantial price increases. The legislation specifically applies to drugs with a wholesale acquisition cost above $40 for a course of therapy and requires notification if the price rises by more than 16% over two years. This targets the most impactful and potentially burdensome increases for consumers and the health system.
Enables public scrutiny while protecting trade secrets. Although companies must disclose price increases and their justifications (including whether improvements to the drug justify the hike), the bill includes protections for trade secrets, balancing transparency with proprietary interests. Aggregated data can be shared publicly without revealing confidential details.
Imposes penalties for non-compliance. Drug manufacturers that fail to report required information face fines of up to $5,000 per day, incentivizing compliance and reinforcing the seriousness of the disclosure requirements.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Notify State of Drug Price Hikes
Plain English, a few words. Used as the page title.
Sponsors
30 Co-sponsors
- Inez E. Dickens
- William Colton
- Jaime R. Williams
- Rebecca Seawright
- Vivian Cook
- Jo Anne Simon
- Jonathan Jacobson
- Pamela J. Hunter
- Jeffrey Dinowitz
- Stefani Zinerman
- David Weprin
- Demond Meeks
- MaryJane Shimsky
- Linda Rosenthal
- Marianne Buttenschon
- Philip Ramos
- Donna Lupardo
- Dana Levenberg
- Albert A. Stirpe
- Jessica Gonzalez-Rojas
- Gina Sillitti
- Kimberly Jean-Pierre
- John T. McDonald III
- Tony Simone
- Grace Lee
- Stacey Pheffer Amato
- John Zaccaro Jr.
- Steven Raga
- Alex Bores
- Karines Reyes
History
- Signed chap.738
- Delivered to governor
- Returned to assembly
- Passed senateVote 52–10
- 3rd reading cal.75
- Substituted for S599A
- Referred to rules
- Delivered to senate
- Passed assembly
- Amended on third reading 1707a
- Restored to third reading
- Substitution reconsidered
Show 6 earlier actions
- Substituted by S599
- Advanced to third reading cal.196
- Reported
- Reported referred to codes
- Reference changed to insurance
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Require Drug Price Hike Notice
Senate Floor Calendar · Sponsor Julia Salazar
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
1707--A Cal. No. 196
2023-2024 Regular Sessions
IN ASSEMBLY
January 18, 2023
Introduced by M. of A. D. ROSENTHAL, DICKENS, COLTON, WILLIAMS, SEAWRIGHT, COOK, SIMON, JACOBSON, HUNTER, DINOWITZ, ZINERMAN, WEPRIN, MEEKS, SHIMSKY, L. ROSENTHAL, BUTTENSCHON, RAMOS, LUPARDO, LEVENBERG, STIRPE, GONZALEZ-ROJAS -- read once and referred to the Committee on Health -- reported and referred to the Committee on Codes -- reported from committee, advanced to a third reading, amended and ordered reprinted, retaining its place on the order of third reading
AN ACT to amend the insurance law, in relation to requiring certain manufacturers of prescription drugs to notify the superintendant of any proposed increase of the wholesale acquisition cost of such prescription drugs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The insurance law is amended by adding a new section 111-a to read as follows:
§ 111-a. Notification of prescription drug price increases by manufacturers. (a) This section shall apply to a manufacturer of a prescription drug that is purchased or reimbursed in this state by any of the following:
(1) An insurance company authorized in this state to write accident and health insurance, a company organized pursuant to article fortythree of this chapter, a municipal cooperative health benefit plan established pursuant to article forty-seven of this chapter, an organization certified pursuant to article forty-four of the public health law, an institution of higher education certified pursuant to section one thousand one hundred twenty-four of this chapter, or the New York state health insurance plan established pursuant to article eleven of the civil service law; or
(2) A pharmacy benefit manager, including an entity that directly or through an intermediary, manages the prescription drug coverage provided by a health insurer under a contract or policy delivered or issued for
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00641-02-3
delivery in this state or a health plan subject to section three hundred sixty-four-j of the social services law, including the processing and payment of claims for prescription drugs, the performance of drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to prescription drug coverage, contracting with network pharmacies, and controlling the cost of covered prescription drugs.
(b) (1) A manufacturer of a prescription drug with a wholesale acquisition cost of more than forty dollars for a course of therapy shall notify the superintendent, his or her deputy or other officer designated by the superintendent, if the increase in the wholesale acquisition cost of such prescription drug is more than sixteen percent, including the proposed increase and the cumulative increases that occurred within the previous twenty-four months prior to the planned effective date of the increase. For purposes of this section, a "course of therapy" is defined as either of the following:
(i) the recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for thirty days; or
(ii) the recommended daily dosage units of a prescription drug pursuant to its prescribing label as approved by the federal Food and Drug Administration for a normal course of treatment that is less than thirty days.
(2) (i) The notice required by paragraph one of this subsection shall be provided in writing to the superintendent at least sixty days prior to the planned effective date of the increase and shall include the proposed increase and the cumulative increases that occurred within the previous twenty-four months.
(ii) The superintendent shall forthwith publish the notice required by paragraph one of this subsection on the department of financial services website within five days of its receipt.
(3) (i) The notice required by paragraph one of this subsection shall include the date of the increase, the current wholesale acquisition cost of the prescription drug, and the dollar amount of the future increase in the wholesale acquisition cost of the prescription drug.
(ii) The notice required by paragraph one of this subsection shall include a statement regarding whether a change or improvement in the drug necessitates the price increase. If so, the manufacturer shall describe the change or improvement.
(4) Information supplied by a manufacturer pursuant to this section that the manufacturer has reasonably designated as a trade secret shall be considered confidential and a trade secret, shall be exempt from public disclosure and copying under article six of the public officers law and shall not be disclosed directly or indirectly by the superintendent. Notwithstanding the foregoing sentence, the superintendent shall be permitted to disclose information in an aggregated format if such aggregate information cannot directly or indirectly be used to identify trade secret information related to a specific manufacturer or the manufacturer's prescription drug, including but not limited to any information related to pricing for the manufacturer's prescription drug that has been reasonably designated as a trade secret.
(5) In the event that a manufacturer of a prescription drug subject to this section does not report the information required in paragraph one of this subsection, the superintendent is authorized to impose any penalty or remedy authorized by this chapter, after notice and a hearing, against such manufacturer of up to five thousand dollars per day for every day after the reporting period described in this section that the required information is not reported.
§ 2. This act shall take effect on the one hundred eightieth day after it shall have become a law.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.